| Authors of models | Name of articles | Journal
|
| Amoxicillin
|
| Zarowny D, Ogilvie R,Tamblyn D, Macleod C, Reudy J.
| Pharmacokinetics of amoxicillin.
| Clin. Pharmacol. Ther. 1974. 16:1045-1051.
|
| Spyker DA, Rugloski RJ, Vann RL, O'Brien WM.
| Pharmacokinetics of Amoxicillin: Dose Dependence After Intravenous, Oral, and Intramuscular Administration.
| Antimicrob Agents Chemother. 1977 January; 11(1): 132-141.
|
| Cefazolin
|
| Polk RE, Kline BJ, Markowitz SM.
| Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion.
| Antimicrob Agents Chemother. 1981 November; 20(5): 576-579.
|
| Cefuroxime
|
| Bundtzen RW, Toothaker RD, Nielson OS, Madsen PO, Welling PG, Craig WA.
| Pharmacokinetics of cefuroxime in normal and impaired renal function: comparison of high-pressure liquid chromatography and microbiological assays.
| Antimicrob Agents Chemother. 1981 March; 19(3): 443-449.
|
| Viberg A.
| Using Pharmacokinetic and Pharmacodynamic Principles to Evaluate Individualisation of Antibiotic Dosing – Emphasis on Cefuroxime.
| Acta Universitatis Upsaliensis. 2006. 57 pp. Uppsala.
|
| Ceftazidime
|
| Eric Dailly, Michel Pannier, Pascale Jolliet, and Michel Bourin.
| Population pharmacokinetics of ceftazidime in burn patients
| Br J Clin Pharmacol. 2003 December; 56(6): 629-634.
|
| Conil JM, Georges B, Lavit M, Laguerre J, Samii K, Houin G, Saivin S.
| A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
| Br J Clin Pharmacol. 2007 Jul;64(1):27-35.
|
| Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sorgel F.
| Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
| J Antimicrob Chemother. 2007 Nov;60(5):1038-44.
|
| Bernard Georges, Jean-Marie Conil, Thierry Seguin, Stephanie Ruiz, Vincent Minville, Pierre Cougot, Jean-Francois Decun, Helene Gonzalez, Georges Houin, Olivier Fourcade and Sylvie Saivin.
| Population Pharmacokinetics of Ceftazidime in Intensive Care Unit Patients: Influence of Glomerular Filtration Rate, Mechanical Ventilation, and Reason for Admission.
| Antimicrob. Agents Chemother. October 2009 vol. 53 no. 10 4483-4489.
|
| Ceftriaxone
|
| Simon N, Dussol B, Sampol E, Purgus R, Brunet P, Lacarelle B, Berland Y, Bruguerolle B, Urien S.
| Population Pharmacokinetics of Ceftriaxone and Pharmacodynamic Considerations in Haemodialysed Patients.
| Clin Pharmacokinet. 2006;45(5):493-501.
|
| Paul G. Ambrose.
| Ceftriaxone. Reappraisal of Food and Drug. Administration In Vitro Susceptibility Test. Interpretive Criteria.
| ICPD, 2010
|
| Cefepime
|
| Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ.
| Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function.
| Antimicrob. Agents Chemother., June 2003, p. 1853–1861
|
| Roos JF, Bulitta J, Lipman J, Kirkpatrick CMJ.
| Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
| Journal of Antimicrobial Chemotherapy (2006) 58, 987–993
|
| Georges B, Conil JM, Seguin T, Dieye E, Cougot P, Decun JF, Lavit M, Samii K, Houin G, Saivin S.
| Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables.
| Int J Clin Pharmacol Ther. 2008 Apr;46(4):157-64.
|
| Nicasio AN, Ariano RE, Zelenitsky SA,Kim A, Crandon JL, Kuti JL, Nicolau DP.
| Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia.
| Antimicrob. Agents Chemother., Apr. 2009, p. 1476–1481
|
| Imipenem
|
| Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sorgel F, Drusano GL, Bertino JS.
| Pharmacokinetics (PK) and Pharmacodynamics (PD) of Imipenem/Cilastatin (I/C) and Meropenem (M) Using 30-Minutes and 3-Hours Infusions in Healthy Volunteers.
| ICAAC 2005 - Antimicrobial Agents and Chemotherapy
|
| Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sorgel F.
| Population Pharmacokinetics and Pharmacodynamics of Continuous versus Short-Term Infusion of Imipenem-Cilastatin in Critically Ill Patients in a Randomized, Controlled Trial.
| Antimicrob Agents Chemother. 2007 September; 51(9): 3304–3310.
|
| Meropenem
|
| Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sorgel F.
| Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
| J Antimicrob Chemother. 2007 Nov;60(5):1038-44.
|
| Doh K, Woo H, Hur J, Yim H, Kim J, Chae H, Han S, Yim DS.
| Population pharmacokinetics of meropenem in burn patients.
| J Antimicrob Chemother. 2010 Nov;65(11):2428-35.
|
| Ciprofloxacin
|
| Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ.
| Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin.
| Antimicrob Agents Chemother. 1993 May; 37(5): 1065–1072.
|
| Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA.
| Population Pharmacokinetics and Use of Monte Carlo Simulation To Evaluate Currently Recommended Dosing Regimens of Ciprofloxacin in Adult Patients with Cystic Fibrosis.
| Antimicrob. Agents Chemother. December 2001 vol. 45 no. 12 3468-3473.
|
| Khachman D, Conil JM, Bernard Georges B, Saivin S, Houin G, Laffont CM
| Population pharmacokinetic analysis of ciprofloxacin in intensive care unit adult patients.
| Abstracts of the Annual Meeting of the Population Approach Group in Europe. p.19 (2010) Abstr 1888.
|
| Khachman D, Conil JM, Bernard Georges B, Saivin S, Houin G, Toutain PL, Laffont CM.
| Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic–pharmacodynamic analysis and Monte Carlo simulations.
| J. Antimicrob. Chemother. (2011)
|
| Levofloxacin
|
| Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Wong FA, Corrado M.
| Levofloxacin Population Pharmacokinetics and Creation of a Demographic Model for Prediction of Individual Drug Clearance in Patients with Serious Community-Acquired Infection.
| Antimicrob. Agents Chemother. May 1998 vol. 42 no. 5 1098-1104
|
| Doxycycline
|
| Agwuh KN, MacGowan A.
| Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.
| Journal of Antimicrobial Chemotherapy (2006) 58, 256–265
|
| Vancomycin
|
| Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, Hori R.
| Population pharmacokinetics of vancomycin in Japanese adult patients.
| Ther Drug Monit. 1998 Apr;20(2):139-48.
|
| Mulla H, Pooboni S.
| Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation.
| Br J Clin Pharmacol. 2005 September; 60(3): 265–275.
|
| Tanaka A, Aiba T, Otsuka T, et al.
| Population Pharmacokinetic Analysis of Vancomycin Using Serum Cystatin C as a Marker of Renal Function.
| Antimicrob Agents Chemother. 2010 February; 54(2): 778–782.
|
